Search Results - "Cuadra, J.L."

1434 POSTER Impact of KRAS Mutations (Krasmut) on Clinical Outcome in Stage IV Non-small Cell Lung Cancer (NSCLC) Patients (pts) and Their Relationship With Other Biomarkers by Cros, S, Capdevila, L, Carcereny, E, Moran, T, Martinez, A, Buges, C, Pardo, N, Cuadra, J.L, Rosell, R

Get full text

374P Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab +/-binimetinib (E-C+/-B) by Ros Montana, F.J., Navarro, V., Comas, R., Garcia Rodriguez, A., Gomez, D., Saoudi Gonzalez, N., Vicente, P., Cuadra, J.L., Paez, D., Alonso, V., Hernandez Martinez, A., López Valbuena, D.E., Baraibar Argota, I., Salvà Ballabrera, F., Tabernero, J., Elez Fernandez, M.E.

Get full text

499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer by Argota, I. Baraibar, Rubio-Pérez, C., Martinez, G. Argiles, Montañá, F.J. Ros, Salvà, F., Margalef, N. Mulet, Urteaga, J.L. Cuadra, Castaneda, D.H. Marmolejo, Gonzalez, N. Saoudi, Ciardiello, D., Tabernero, J., Seoane, J., Elez, E.

Get full text

9054 POSTER Hypofractioned Prophylactic Radiotherapy for Pleural Malignant Mesothelioma – a Review of a 7-year Single Institutional Experience by Moretones, C, Cuadra-Urteaga, J.L, Jove, J, Caro, M, Villa, S, Arellano, A

Get full text

Efficacy and Prognostic Factors of Neoadjuvant Chemotherapy in Resectable Locally-Advanced Muscle-Invasive Bladder Cancer (MIBC) Patients (P) in an Off-Protocol Clinical Setting by Urteaga, J.L. Cuadra, Domenech, M., Celiz, P., Sánchez, J.J., Pardo, N., Buges, C., Malet, J., Arzoz, M., Areal, J., Font, A.

Get full text

Outcome to Neoadjuvant Cisplatin-Based Chemotherapy in Resectable Muscle-Invasive Bladder Cancer (MIBC) Patients (P) According to Expression Levels of BRCA1, RAP80, and AEG-1 by Pardo, N., Celiz, P., Font, A., Taron, M., Chaib, I., Mendez, P., Sánchez, J.J., Sanchez, B., Urteaga, J.L. Cuadra, Rosell, R.

Get full text

426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care by Valdivia, A.A., Salva, F., Ros, J., Baraibar, I., Argiles Martinez, G., Saoudi Gonzalez, N., Garcia, A., Mulet Margalef, N., Cuadra Urteaga, J.L., Capdevila, J., Salud Salvia, M.A., Paez, D., Casado, E., Comas, R., Ruiz-Pace, F., Villacampa Javierre, G., Acosta Eyzaguirre, D.A., Dienstmann, R., Elez Fernandez, M.E., Tabernero, J.

Get full text

461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR) by Argota, I. Baraibar, Ros, J., Comas, R., Aguilar, S., Salva, F., Garcia, A., Cuadra Urteaga, J.L., Saoudi Gonzalez, N., Mulet Margalef, N., Hernando, J., Capdevila, J., Martí, M., Espín, E., Garralda, E., Nuciforo, P., Dienstmann, R., Vivancos, A., Tabernero, J., Elez Fernandez, M.E.

Get full text

434PRECHALLENGE WITH BEVACIZUMAB (BEV) IN PATIENTS (P) WITH GLIOBLASTOMA (GBM) AND PREVIOUS OBJECTIVE RESPONSE TO BEV by Indacochea, A., Estival, A., Ahlal, S., Etxaniz, O., Gil, M.D.L.L., Vila, L., Cuadra Urtega, J.L., Carrato, C., Balana, C.

“…Abstract Aim: GBM is the most common primary brain tumor and is characterized by high vascularitzation and overexpression of vascular endothelial growth factor…”
Get full text

Rechallenge with Bevacizumab (Bev) in Patients (P) with Glioblastoma (Gbm) and Previous Objective Response to Bev by Indacochea, A., Estival, A., Ahlal, S., Etxaniz, O., Gil, M.D.L.L., Vila, L., Cuadra Urtega, J.L., Carrato, C., Balana, C.

Get full text

Second Primary Malignances (Spms) in Patients (P) with Gastrointestinal Stromal Tumors (Gists) – a Coincidence or an Effect of Imatinib? by Estival, A., Etxaniz, O., Cuadra Urteaga, J.L., Romeo, M., Blanco, I., Gil, M., Ahlal, S., Ojanguren, I., Indacochea, A., Vila, L., Balana, C.

Get full text

1432PSECOND PRIMARY MALIGNANCES (SPMS) IN PATIENTS (P) WITH GASTROINTESTINAL STROMAL TUMORS (GISTS) – A COINCIDENCE OR AN EFFECT OF IMATINIB? by Estival, A., Etxaniz, O., Cuadra Urteaga, J.L., Romeo, M., Blanco, I., Gil, M., Ahlal, S., Ojanguren, I., Indacochea, A., Vila, L., Balana, C.

“…Abstract Aim: GISTs are the most common mesenchymal tumors of the gastrointestinal tract. Imatinib has become the standard treatment for unresectable…”
Get full text

Los pacientes y la calidad de los servicios de atención primaria de salud. Opinión de los profesionales de los centros de salud de la Bahía de Cádiz y La Janda by Hernán García, M., Gutiérrez Cuadra, J.L., Lineros González, C., Ruiz Barbosa, C., Rabadán Asensio, A.

“…Conocer la opinión de los profesionales de los centros de salud (CS) sobre las dimensiones de la calidad que afectan a la satisfacción de los usuarios. Estudio…”
Get full text